More on CBIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $12.82 |
|
|||
| Open | $12.87 | ||||
| 52 Wk High | $4.57 | ||||
| 52 Wk Low | $0.62 | ||||
| Day High | $13.27 | ||||
| Day Low | $12.50 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 62,085 | ||||
- H.C. Wainwright Reiterates Buy Rating on Crescent Biopharma Inc (CBIO)
- Crescent Biopharma (CBIO) Reiterated at Buy by Stifel on Comprehensive Pipeline Update
- Crescent Biopharma expands CR-001 trial with chemo combos
- Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis
- Crescent Biopharma Announces Grants of Inducement Awards
- Crescent Biopharma (CBIO) Reiterated at Buy by Stifel
- H.C. Wainwright Upgrades Crescent Biopharma Inc (CBIO) to Buy
- FDA clears Crescent Biopharma IND for CR-002 solid tumor ADC
- Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
- Crescent Biopharma Announces Grants of Inducement Awards
Entities mentioned with CBIO
- FDA | View Related Stories »
- 13G | View Related Stories »
- 13D | View Related Stories »
- S3 | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Raymond James | View Related Stories »
- Ladenburg Thalmann Financial Services | View Related Stories »
- Show More...
